Surging Cancer Prevenance Drives DNA Microarray Market 

In 2023, the worldwide DNA microarray industry produced revenue of USD 1,982.1 million, which will attain USD 3,930.8 million by the end of the decade, growing at 10.5% CAGR during the projection period.

The development of this market can be explained by the increase in awareness and use of this technology in the detection process and IT world and, the evolution of software for it. DNA microarray has several applications ranging from agricultural biotechnology to disease diagnosis & monitoring, to protein expression & proteomics, and so on.

DNA microarrays are an ongoing advancement in the specially designed pathway for the very purpose of - diagnosis and prognosis, targeted therapies, and many other conditions. First of all, the treatment methods of the diseases through the traditional way they cannot make the precise diagnosis and treat the disease. Because of that, personalized medicine has come to be considered. 

These diseases comprising of cancer and immune disorders are the most threatening of the bunch which bring great implications on each person's prognosis and treatment by considering the acquisition of full genome understanding. Thus, along with this rise in the number of individuals who are in favor of tailored medicine, we can see the expansion of the industry.

The DNA microarray is a crucial component that is everywhere in genome mapping and sequencing processes. However, despite of this quite recent observation, the application of these microarray studies rose in diagnostics and detection of diseases of infectious origin, genetic basis of diseases, cancer diagnostics, new drugs research, pharmacogenomics, etc.

Key Insights

1. The oligonucleotide DNA microarray category held the largest share, 70%, and is estimated to uphold supremacy because of cost-efficiency and accurate gene expression monitoring abilities.
2. It has the potential to screen hybridization specificity and therefore is regarded as a key technique for researching single nucleotide polymorphisms (SNPs).
3. The cDNA microarray segment is projected to record the highest CAGR, given the vital applications of this technology in studying gene expression across several species.
4. In 2023, the pharmaceutical & biotechnology industry held the largest share, of more than 40%, and the category is also projected to remain dominant because of augmented acceptance of DNA microarrays in drug discovery and research.
5. Development in research activities for finding new drug molecules supports industry growth in this category.
6. DNA microarrays are attaining significance in cancer research, classifying molecular markers with diagnostic potential for numerous human cancers.
7. Hospitals & diagnostic centers will witness the fastest development, propelled by the acceptance of DNA microarray tech in clinical diagnostics.
8. Advanced laboratories utilize DNA microarrays for detecting numerous polymorphisms in a single assay using biochips.
9. In 2023, the North American region had a significant share, around 40%, and is forecasted to advance at a strong CAGR.
10. Major reasons propelling this development include the existence of key industry players investing in technically enhanced DNA microarray items.
11. The continent witnessed a surge in difficult-to-diagnose and treat diseases, leading to augmented demand for microarrays.
12. Canada's market is growing rapidly with the boom of superior healthcare infrastructure, government support systems initiating perfect diabetes, and the surge of chronic diseases.
13. Revenue dynamics in the healthcare sector, in particular biotechnology, are largely influenced by innovative investments in North America.

SOURCE: P&S Intelligence